netLibrary - eBook Summary Structure-based Drug Design by ...

More documents

Recommendations

Info

Document Figure 2 Structure-based drug design strategy. Page 153 A tight fit is necessary for potency and specificity. A drug that binds to its target and inactivates it for a long time can be administered in lower doses than one that rapidly separates from its target. A substance designed to mesh perfectly with a particular binding site of one target is unlikely to interact well with any other molecule, minimizing unwanted interactions and side effects. Having chosen PNP as the target, we followed a systematic strategy for designing inhibitory compounds. Figure 2 outlines the overall strategy of this approach. To serve as a drug, an inhibitor has to readily cross cell membranes to the interior of cells, where PNP is located. http://legacy.netlibrary.com/nlreader/nlReader.dll?bookid=12640&filename=Page_153.html (1 of 2) [4/5/2004 5:01:14 PM]
Document We determined the structure of human PNP by x-ray crystallography and used these results in combination with computer-assisted molecular modeling to design inhibitor candidates. We examined how well the shape and chemical http://legacy.netlibrary.com/nlreader/nlReader.dll?bookid=12640&filename=Page_153.html (2 of 2) [4/5/2004 5:01:14 PM]
Page 1 and 2:
netLibrary - eBook Summary Universi
Page 3 and 4:
Structure-based Drug Design 14 Stru
Page 5 and 6:
Document p17, p9, and p7) and repli
Page 7 and 8:
Document Figure 1 Stereo view of th
Page 9 and 10:
Document Figure 2 Schematic represe
Page 11 and 12:
Document TF—transframe, PR—prot
Page 13 and 14:
Document compounds that utilize sim
Page 15 and 16:
Document Page 11 retroviral substra
Page 17 and 18:
Document Page 13 of the active-site
Page 19 and 20:
Document Page 15 Thiazoles are less
Page 21 and 22:
Document Page 17 the resulting chim
Page 23 and 24:
Document http://legacy.netlibrary.c
Page 25 and 26:
Document Figure 5 Stereo view AG134
Page 27 and 28:
Document Page 23 potentially loweri
Page 29 and 30:
Page 31 and 32:
Document Page 27 volume of the acti
Page 33 and 34:
Document Figure 7 Cartoon represent
Page 35 and 36:
Document Figure 8 Cartoon represent
Page 37 and 38:
Document Page 33 sustained in many
Page 39 and 40:
Document 8. Kaplan AH, Zack JA, Kni
Page 41 and 42:
Document 22. Krausslich HG, Ingraha
Page 43 and 44:
Document 35. Kaldor SW, Hammond M,
Page 45 and 46:
Document 47. Tummino PJ, Ferguson D
Page 47 and 48:
Document 60. Condra JH, Schleif WA,
Page 49 and 50:
Document 74. Reddy RM, Varney MD, K
Page 51 and 52:
Document 2 Structural Studies of HI
Page 53 and 54:
Document Figure 1 (a) Chemical stru
Page 55 and 56:
Document dine (3TC), and 2',3'-dide
Page 57 and 58:
Document Figure Continued Page 45 r
Page 59 and 60:
Document Figure 2 Ribbon diagrams o
Page 61 and 62:
Document Figure 3 Overall structure
Page 63 and 64:
Document monophosphate analogs whic
Page 65 and 66:
Document Analysis of various HIV-1
Page 67 and 68:
Document Page 54 Table 2) [12,54].
Page 69 and 70:
Document Page 56 It is also attract
Page 71 and 72:
Document Table 3 HIV-1 RT Amino Aci
Page 73 and 74:
Document ever, once an NNRTI is bou
Page 75 and 76:
Document Page 61 now clear that the
Page 77 and 78:
Document Page 63 most of the amino
Page 79 and 80:
Document Page 65 cal properties of
Page 81 and 82:
Document Page 67 Biochemical data s
Page 83 and 84:
Document Page 69 determining the me
Page 85 and 86:
Document Chris Tantillo. The work i
Page 87 and 88:
Document Page 72 16. Goldman ME, Nu
Page 89 and 90:
Document 30. Coffin JM. HIV populat
Page 91 and 92:
Document 45. Majumadar C, Abbotts J
Page 93 and 94:
Document reverse transcriptase inhi
Page 95 and 96:
Document 75. Ring CS, Sun E, McKerr
Page 97 and 98:
Document 89. Hughes SH, Arnold E, H
Page 99 and 100:
Document 106. Cirino NM, Cameron CE
Page 101 and 102:
Document 122. Marshall WS, Beaton G
Page 103 and 104:
Document dine) and didanosine (dide
Page 105 and 106:
Document 149. Craig JC, Duncan IB,
Page 107 and 108:
Document 163. Lacey SF, Larder BA.
Page 109 and 110:
Document Figure 1 Retroviral lifecy
Page 111 and 112:
Document Figure 2 In vivo reactions
Page 113 and 114:
Document Page 88 transfer (Figure 3
Page 115 and 116:
Page 117 and 118:
Document Page 92 The role of the N-
Page 119 and 120:
Document Figure 6 Molscript stereo
Page 121 and 122:
Document Page 96 region in the HIV-
Page 123 and 124:
Document day junction resolving enz
Page 125 and 126:
Document -62° for HIV-1 integrase,
Page 127 and 128:
Document Page 101 crystallized unde
Page 129 and 130:
Document Figure 8 Molscript stereo
Page 131 and 132:
Document proposed mechanisms. For e
Page 133 and 134:
Document Page 106 on the same ring
Page 135 and 136: Document Page 108 mulate during tre
Page 137 and 138: Document when metals are bound. Fin
Page 139 and 140: Document cubation of phosphotyrosin
Page 141 and 142: Document 4. Vink C, Plasterk RHA. T
Page 143 and 144: Document Page 115 21. Kulkosky J, J
Page 145 and 146: Document 44. Cushman M, Sherman P.
Page 147 and 148: Document 65. Gallay P, Swingler S,
Page 149 and 150: Document 4 Bradykinin Receptor Anta
Page 151 and 152: Document Page 121 Nearly all cells
Page 153 and 154: Document Page 123 were poorly satis
Page 155 and 156: Document Page 125 binding site on t
Page 157 and 158: Document Page 127 The des-Arg 9 for
Page 159 and 160: Document Page 129 tolerated by the
Page 161 and 162: Document receptor, it has not yet b
Page 163 and 164: Document Page 133 This initial stag
Page 165 and 166: Document Page 135 might be jointly
Page 167 and 168: Document Page 137 observed for the
Page 169 and 170: Document Figure 6 Rat and human B2
Page 171 and 172: Document Page 141 receptor with int
Page 173 and 174: Document http://legacy.netlibrary.c
Page 175 and 176: Document Figure 9 Composition of te
Page 179 and 180: Document 16. Martorana PA, Kettenba
Page 181 and 182: Document 39. Mavunkel BJ, Lu Z, Kyl
Page 183 and 184: http://legacy.netlibrary.com/reader
Page 185: Document B. Pharmacology Figure 1 T
Page 189 and 190: Document Figure 3 Previously known
Page 195 and 196: Document large solvent channels and
Page 197 and 198: Document IV. Drug Design Progressio
Page 199 and 200: Document position eight from formin
Page 201 and 202: Document Table 1 Inhibition Data fo
Page 203 and 204: Document Page 166 As predicated, th
Page 205 and 206: Document References 1. Parks RE Jr.
Page 207 and 208: Document 17. Ealick SE, Rule SA, Ca
Page 209 and 210: Document 6 Structural Implications
Page 211 and 212: Document Figure 1 A ribbon model of
Page 215 and 216: Document Page 176 0.43 Å) as the c
Page 217 and 218: Document Page 178 studies show that
Page 219 and 220: Document Figure 5 (a) A cut away vi
Page 221 and 222: Document Page 182 (SAR) model. The
Page 223 and 224: Document IX. S2' Interactions Page
Page 225 and 226: Document Figure 6 (a) The pocket of
Page 227 and 228: Document 5. Willenbrock F, Murphy G
Page 229 and 230: Document 20. Murphy G, Docherty AJP
Page 231 and 232: Document Page 189 36. Bode W, Reine
Page 233 and 234: Document 7 Structure—Function Rel
Page 235 and 236: Document Figure 1 Reactions catalyz
Page 237 and 238:
Document Figure 2 Structure of lico
Page 239 and 240:
Document Figure 3 (Continued) Page
Page 241 and 242:
Document Important for the validity
Page 243 and 244:
Document Figure 4 Amino acids impor
Page 245 and 246:
Document III. Results and Discussio
Page 247 and 248:
Document Page 202 269, and valine-2
Page 249 and 250:
Document Figure 6 Structure of α h
Page 251 and 252:
Document Page 205 enzyme and of phe
Page 253 and 254:
Document Page 207 sure and the acti
Page 255 and 256:
Document 13. Wilson RC, Krozowski Z
Page 257 and 258:
Document 29. Baker ME. Genealogy of
Page 259 and 260:
Document 46. Ribas dePoplana L, Fot
Page 261 and 262:
http://legacy.netlibrary.com/reader
Page 263 and 264:
Document Page 214 viruses. Specific
Page 265 and 266:
Document Figure 1 (Continued) this
Page 267 and 268:
Document Page 218 The catalytic loo
Page 269 and 270:
Document Page 220 conserved substra
Page 271 and 272:
Document Figure 3 (a) Ternary compl
Page 273 and 274:
Document Figure 5 (a) Staurosporine
Page 275 and 276:
Document protein kinase core is ess
Page 277 and 278:
Document 10. Knighton DR, Zheng J-H
Page 279 and 280:
Document 24. Madhusudan Xuong N-H,
Page 281 and 282:
Document 9 Structural Studies of Al
Page 283 and 284:
Document diverse ARIs have been sho
Page 285 and 286:
Document Figure 3 C α trace of the
Page 287 and 288:
Document Figure 4 Surface represent
Page 289 and 290:
Page 291 and 292:
Document Figure 7 Stereo of zopolre
Page 293 and 294:
Document B. Structures Figure 8 Seq
Page 295 and 296:
Document This method was used to sc
Page 297 and 298:
Document 2. Lee AYW, Chung SK, Chun
Page 299 and 300:
Document 18. Wilson DK, Tarle I, Pe
Page 301 and 302:
Document 35. Pailhoux EA, Martinez
Page 303 and 304:
Document 10 Structure-Based Design
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Document Cyclotheonamide A (CtA), a
Page 313 and 314:
Document Page 256 The discovery pro
Page 315 and 316:
Page 317 and 318:
Document et al. [21]). Among these
Page 319 and 320:
Document balance its pro- and antic
Page 321 and 322:
Document Page 263 15. Tabernero L,
Page 323 and 324:
Document 31. Kettner C, Shaw E. D-P
Page 325 and 326:
Document Figure 1 The coagulation c
Page 327 and 328:
Document Figure 2 Factor Xa structu
Page 329 and 330:
Document Table 2 Naturally Occurrin
Page 331 and 332:
Document Table 3 Active Site Sequen
Page 333 and 334:
Document Figure 5 Predicted seconda
Page 335 and 336:
Document Lys in the P1 position is
Page 337 and 338:
Document Page 276 In both cases the
Page 339 and 340:
Document Page 278 The n=3 chain len
Page 341 and 342:
Document Figure 10 Proposed model o
Page 343 and 344:
Document Figure 11 dArg-ATS 32-38 m
Page 345 and 346:
Document Figure 12 Modeled fit of S
Page 347 and 348:
Document Page 285 number of x-ray s
Page 349 and 350:
Page 351 and 352:
Document Page 288 Additionally, the
Page 353 and 354:
Document Page 290 5. Kaiser B, Haup
Page 355 and 356:
Document Page 291 21. Davie EW, Fuj
Page 357 and 358:
Document 36. Leytus SP, Chung DW, K
Page 359 and 360:
Document 54. Broze Jr GJ, Girard TJ
Page 361 and 362:
Document Page 294 70. Seligmann B,
Page 363 and 364:
Document 12 Polypeptide Modulators
Page 365 and 366:
Document Page 297 whereas, calcium
Page 367 and 368:
Document Figure 2 Amino acid sequen
Page 369 and 370:
Document Page 301 domains contribut
Page 371 and 372:
Document Figure 5 Stereo views of 2
Page 373 and 374:
Document A. Chemical Modification P
Page 375 and 376:
Document Page 307 (the exception is
Page 377 and 378:
Document Page 309 site 3 on the sod
Page 379 and 380:
Page 381 and 382:
Document Page 312 In peptide—prot
Page 383 and 384:
Document Page 314 anemone toxins an
Page 385 and 386:
Document 5. Packer M, Gheorghiade M
Page 387 and 388:
Document 25. Malpezzi ELA, De Freit
Page 389 and 390:
Document 42. Catterall WA, Beress L
Page 391 and 392:
Document 60. Pennington MW, Zadenbe
Page 393 and 394:
Document 76. Gould AR, Mabbutt BC,
Page 395 and 396:
Document 13 Rational Design of Reni
Page 397 and 398:
Document Page 323 been suggested th
Page 399 and 400:
Document Figure 2 A schematic diagr
Page 401 and 402:
Document Page 327 this analog inter
Page 403 and 404:
Document Page 329 binding involves
Page 405 and 406:
Document plasma. This may arise fro
Page 407 and 408:
Document C. Specificity Figure 4 Th
Page 409 and 410:
Document Figure 5 The S 3 specifici
Page 411 and 412:
Document IV. Rational Drug Design F
Page 413 and 414:
Document 2. Blundell TL, Cooper J,
Page 415 and 416:
Document 17. Szelke M. Chemistry of
Page 417 and 418:
Document 34. Rosenberg SH, Plattner
Page 419 and 420:
Document 48. Powers JC, Harley AD,
Page 421 and 422:
Document Page 343 14 Structural Asp
Page 423 and 424:
Document Figure 2 The reaction cata
Page 425 and 426:
Document Figure 4 Amino acid sequen
Page 427 and 428:
Document Figure 5 Schematic stereo
Page 429 and 430:
Document Figure 8 The catalytic mac
Page 431 and 432:
Document Figure 10 Structures of so
Page 433 and 434:
Document From quantitative structur
Page 435 and 436:
Document Page 355 with the tryptoph
Page 437 and 438:
Document Figure 14 The energy profi
Page 439 and 440:
Document Page 359 easily reach the
Page 441 and 442:
Document Page 361 2. Guldberg H, Ma
Page 443 and 444:
Document Page 362 19. Lotta T, Vidg
Page 445 and 446:
Document 35. Davis TL, Roznoski M,
Page 447 and 448:
Page 449 and 450:
Document Figure 1 Available drugs f
Page 451 and 452:
Document Table 1 Trypanosomal Targe
Page 453 and 454:
Document Table 2 Three-Dimensional
Page 455 and 456:
Document Figure 2 Glycolysis in blo
Page 457 and 458:
Document II. Three Glycolytic Enzym
Page 459 and 460:
Document Figure 4 Stereoview of sup
Page 461 and 462:
Document Figure 6 Stereoview of NAD
Page 463 and 464:
Document Page 376 was recently solv
Page 465 and 466:
Document Because there are no known
Page 467 and 468:
Document Page 379 For trypanosomal
Page 469 and 470:
Page 471 and 472:
Document Because there are tens of
Page 473 and 474:
Document 5-Methoxytryptamine 19.0 9
Page 475 and 476:
Document Figure 11 Two-dimensional
Page 477 and 478:
Document Figure 12 Predicted bindin
Page 479 and 480:
Document Page 388 nosine proved to
Page 481 and 482:
Document 15. Carter NS, Fairlamb AH
Page 483 and 484:
Document 30. Kim H, Feil I, Verlind
Page 485 and 486:
Document 49. Michels PAM, Hannaert
Page 487 and 488:
Document 65. João HC, Williams RJP
Page 489 and 490:
Document 84. Verlinde CLMJ, Hol WGJ
Page 491 and 492:
Document 16 Progress in the Design
Page 493 and 494:
Document Table 1 Known Three-Dimens
Page 495 and 496:
Document Page 398 with growth hormo
Page 497 and 498:
Document All effects of the IL-1 fa
Page 499 and 500:
Document has a single membrane-span
Page 501 and 502:
Document Figure 2 Structural alignm
Page 503 and 504:
Document Page 405 strands constitut
Page 505 and 506:
Document Figure 4 (a) Stereo diagra
Page 507 and 508:
Document Figure 6 (a) Stereo diagra
Page 509 and 510:
Document Figure 7 (a) Superposition
Page 511 and 512:
Document Page 412 ture is unlike ot
Page 513 and 514:
Document Figure 10 Schematic diagra
Page 515 and 516:
Document Page 416 positions of the
Page 517 and 518:
Document Figure 11 Functional resid
Page 519 and 520:
Document Figure 13 The identified p
Page 521 and 522:
Document B. Interleukin-1 Receptor
Page 523 and 524:
Document Page 423 American Home Pro
Page 525 and 526:
Document Page 425 Antinflammatory D
Page 527 and 528:
Document Page 427 These aromatic di
Page 529 and 530:
Document 5. Dinarello CA. On the Bi
Page 531 and 532:
Document 21. Seckinger P, Lowenthal
Page 533 and 534:
Document 39. Saurat JH, Schfferli J
Page 535 and 536:
Document receptor antagonist into a
Page 537 and 538:
Document 74. Bender PE, Lee JC., ed
Page 539 and 540:
Document 102. Machin PJ, Osbond JM,
Page 541 and 542:
Document 17 Structure and Functiona
Page 543 and 544:
Document Table 1 Approval Indicatio
Page 545 and 546:
Document Page 438 proteins. One pot
Page 547 and 548:
Document II. Type IFNs A great deal
Page 549 and 550:
Document Page 441 sequence of the m
Page 551 and 552:
Document Page 443 that allowed for
Page 553 and 554:
Document Figure 4 Stereo view of IF
Page 555 and 556:
Document Figure 5 Velcro-key model
Page 557 and 558:
Document Figure 6 Proposed receptor
Page 559 and 560:
Document Page 451 with the cytoplas
Page 561 and 562:
Document for directed subcellular t
Page 563 and 564:
Document 13. Stewart HJ, McCann SHE
Page 565 and 566:
Document 33. Szente BE, Johnson HM.
Page 567 and 568:
Document 47. Igarashi K, Garotta G,
Page 569 and 570:
Page 571 and 572:
Document Figure 1 A schematic diagr
Page 573 and 574:
Document Page 462 strains of influe
Page 575 and 576:
Document Page 464 could not again b
Page 577 and 578:
Document Figure 3 (a) A MOLSCRIPT [
Page 579 and 580:
Document B. Protein Structure Page
Page 581 and 582:
Document Figure 5 (a) Stereo image
Page 583 and 584:
Document Page 471 molecules in the
Page 585 and 586:
Document hydroxy, and 6 Neu5Ac2en -
Page 587 and 588:
Document Figure 8 Stereo image of t
Page 589 and 590:
Document Page 476 nM, respectively.
Page 591 and 592:
Document Page 478 lished—was asso
Page 593 and 594:
Document VI. Conclusion Page 480 It
Page 595 and 596:
Document 21. Both GW, Sleigh MJ, Co
Page 597 and 598:
Document 40. Drzenick R, Frank H, R
Page 599 and 600:
Document 45. Varghese JN, Laver WG,
Page 601 and 602:
Document 64. Ward CW, Elleman TC, A
Page 603 and 604:
Document 80. Suzuki Y, Sato K, Kiso
Page 605 and 606:
Document Page 486 95. Ryan DM, Tice
Page 607 and 608:
Document Page 488 against most of t
Page 609 and 610:
Page 611 and 612:
Document A. The Canyon Page 491 The
Page 613 and 614:
Document Subsequent studies have sh
Page 615 and 616:
Document Page 495 of the RNA and pr
Page 617 and 618:
Document Figure 4 A ribbon diagram
Page 619 and 620:
Document Figure 5 Some compounds wh
Page 621 and 622:
Document Figure 7 HRV14 VP1 hydroph
Page 623 and 624:
Document C. Structure-Activity Rela
Page 625 and 626:
Page 627 and 628:
Page 629 and 630:
Document Hydrophobicity Requirement
Page 631 and 632:
Document Figure 9 A solvent-accessi
Page 633 and 634:
Document accommodate a variety of d
Page 635 and 636:
Document Figure 10 Possible hydroge
Page 637 and 638:
Document Page 514 sis. Large number
Page 639 and 640:
Document conformational transition
Page 641 and 642:
Document Page 518 The differences b
Page 643 and 644:
Document 10. Mast EE, Harmon MW, Gr
Page 645 and 646:
Document 25. Arnold E, Rossmann MG.
Page 647 and 648:
Document 44. Argos P, Rossmann MG,
Page 649 and 650:
Document 63. Rozhon E, Cox S, Buont
Page 651 and 652:
Document 81. Diana GD, McKinlay MA,
Page 653 and 654:
Document 20 The Integration of Stru
Page 655 and 656:
Document Page 527 function. Iterati
Page 657 and 658:
Document Figure 3 Generation of com
Page 659 and 660:
Document Page 530 screen. For examp
Page 661 and 662:
Document ciency of drug discovery (
Page 663 and 664:
Document Page 533 the reactions are
Page 665 and 666:
Document Page 535 by factoring in a
Page 667 and 668:
Document Page 537 ries, holds the p
Page 669 and 670:
Document 17. Zuckermann RN, Martin
Page 671 and 672:
Document 34. Fei Y-J, Kanai Y, Nuss
Page 673 and 674:
Document 21 Structure-Based Combina
Page 675 and 676:
Page 677 and 678:
Document Page 545 protein binding s
Page 679 and 680:
Page 681 and 682:
Document Figure 3 (a) Stereo view o
Page 683 and 684:
Page 685 and 686:
Document Lists of Bonding Fragment
Page 687 and 688:
Document Figure 8 Minimized structu
Page 689 and 690:
Document Page 555 N-acylpyrrolidine
Page 691 and 692:
Document 10. Bobbyer DNA, Goodford
Page 693 and 694:
Document structure. 2. Ligand probe
Page 695 and 696:
Document 30. O'Shea EK, Rutkowski R
Page 697 and 698:
Document 22 Peptidomimetic and Nonp
Page 699 and 700:
Document Figure 1 Examples of nativ
Page 701 and 702:
Document B. Peptidomimetic Drugs: C
Page 703 and 704:
Document Figure 4 Backbone amide bo
Page 705 and 706:
Document 12640-0567a.gif Figure 6 C
Page 707 and 708:
Document Page 569 molecule. A nonco
Page 709 and 710:
Document cases, a pharmacophore mod
Page 711 and 712:
Document Figure 9 Peptide scaffold-
Page 713 and 714:
Document Figure 11 Protease-targete
Page 715 and 716:
Document Figure 12 Peptide scaffold
Page 717 and 718:
Page 719 and 720:
Document Figure 14 Signal-transduct
Page 721 and 722:
Page 723 and 724:
Page 725 and 726:
Document Figure 17 Nonpeptide drug
Page 727 and 728:
Page 729 and 730:
Page 731 and 732:
Document Page 591 often suggest tha
Page 733 and 734:
Document Page 593 versus antagonist
Page 735 and 736:
Document Page 595 the MC1 receptor
Page 737 and 738:
Page 739 and 740:
Document Figure 22 Protease 3D stru
Page 741 and 742:
Document Page 601 inhibitors 100 [1
Page 743 and 744:
Document Page 603 hydroxymethyl sub
Page 745 and 746:
Document Page 605 For other serinyl
Page 747 and 748:
Document Page 607 scopic studies pr
Page 749 and 750:
Document Page 609 (e.g., thermolysi
Page 751 and 752:
Page 753 and 754:
Page 755 and 756:
Document (Ser/Thr) peptide 2.9 Å 2
Page 757 and 758:
Page 759 and 760:
Page 761 and 762:
Document Page 617 Val (131) showed
Page 763 and 764:
Document Figure 32 PTP and PTB 3D s
Page 765 and 766:
Document Acknowledgments Page 620 I
Page 767 and 768:
Document 18. Sawyer TK. In: Peptide
Page 769 and 770:
Document Page 622 Fukuroda T, Fukam
Page 771 and 772:
Document Page 623 53. Bird J, Harpe
Page 773 and 774:
Document 78. Rodriguez M, Crosby R,
Page 775 and 776:
Document MA, Welch KM, Hallak H, Ta
Page 777 and 778:
Document Page 626 SJ, Ogden RC, Red
Page 779 and 780:
Document 97; (e) Fujii I, Nakamura
Page 781 and 782:
Document Med Biol 1991; 306:9-21; (
Page 783 and 784:
Document Page 629 ML, Clare M, Decr
Page 785 and 786:
Document Page 630 177. (a) Bode W,
Page 787 and 788:
Document Page 631 197. Musil D, Zuc
Page 789 and 790:
Document son AH, Drummond AH, Huxle
Page 791 and 792:
Document 236. (a) Marshall MS. TIBS
Page 793 and 794:
Page 795 and 796:
Document 274. (a) Kavanaugh WM, Wil
Page 797 and 798:
Document replacements, 563-565 1-am
Page 799 and 800:
Document inhibitor binding, 323, 33
Page 801 and 802:
Document site, 52, 55, 61 triad, 24
Page 803 and 804:
Document factors, 247 Combination t
Page 805 and 806:
Document Cyclotheonamide A (CtA), 2
Page 807 and 808:
Document D ddI, 152 tumour necrosis
Page 809 and 810:
Document antistasin peptides, 281 c
Page 811 and 812:
Document fragment-based programs, 5
Page 813 and 814:
Document [Human immunodeficiency vi
Page 815 and 816:
Document overview, 103-104, 108-109
Page 817 and 818:
Document [Inhibitors] 2-((3,4-dihyd
Page 819 and 820:
Document antagonistic activity, 416
Page 821 and 822:
Document [Interleukin-1] homology w
Page 823 and 824:
Document Kininogen, 119 high molecu
Page 825 and 826:
Document Matrix-metalloproteinase (
Page 827 and 828:
Document RT inhibitor, 41, 56 Nonpe
Page 829 and 830:
Document Phosphoglycerate kinase (P
Page 831:
Document [Protease targets] serinyl
show all

netLibrary - eBook Summary Structure-based Drug Design by ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?